293 related articles for article (PubMed ID: 7850324)
1. The persistence of bacille Calmette-Guérin in the bladder after intravesical treatment for bladder cancer.
Bowyer L; Hall RR; Reading J; Marsh MM
Br J Urol; 1995 Feb; 75(2):188-92. PubMed ID: 7850324
[TBL] [Abstract][Full Text] [Related]
2. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guérin for carcinoma in situ of the bladder.
Merz VW; Marth D; Kraft R; Ackermann DK; Zingg EJ; Studer UE
Br J Urol; 1995 Feb; 75(2):180-4. PubMed ID: 7850322
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
Lamm DL; Blumenstein BA; Crawford ED; Montie JE; Scardino P; Grossman HB; Stanisic TH; Smith JA; Sullivan J; Sarosdy MF
N Engl J Med; 1991 Oct; 325(17):1205-9. PubMed ID: 1922207
[TBL] [Abstract][Full Text] [Related]
4. The fate of bacillus Calmette-Guerin after intravesical instillation.
Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
[TBL] [Abstract][Full Text] [Related]
5. Intravesical Evans Bacille Calmette-Guérin in the treatment of carcinoma in situ.
Cumming JA; Hargreave TB; Webb JN; McIntyre MA; Chisholm GD
Br J Urol; 1989 Mar; 63(3):259-63. PubMed ID: 2702423
[TBL] [Abstract][Full Text] [Related]
6. Impact of Adjuvant Intravesical Bacillus Calmette-Guérin Treatment on Patients with High-Grade T1 Bladder Cancer.
Novotny V; Froehner M; Ollig J; Koch R; Zastrow S; Wirth MP
Urol Int; 2016; 96(2):136-41. PubMed ID: 26789626
[TBL] [Abstract][Full Text] [Related]
7. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
[TBL] [Abstract][Full Text] [Related]
8. Systemic bacillus Calmette-Guerin infection in patients treated by intravesical BCG therapy for superficial bladder cancer.
Steg A; Leleu C; Debré B; Boccon-Gibod L; Sicard D
Prog Clin Biol Res; 1989; 310():325-34. PubMed ID: 2672020
[TBL] [Abstract][Full Text] [Related]
9. Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma.
Falkensammer C; Gozzi C; Hager M; Maier H; Bartsch G; Höltl L; Rehder P
Urology; 2005 Jan; 65(1):175. PubMed ID: 15667898
[TBL] [Abstract][Full Text] [Related]
10. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
Luciani LG; Neulander E; Murphy WM; Wajsman Z
Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
[TBL] [Abstract][Full Text] [Related]
11. Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity.
Lam JS; Benson MC; O'Donnell MA; Sawczuk A; Gavazzi A; Wechsler MH; Sawczuk IS
Urol Oncol; 2003; 21(5):354-60. PubMed ID: 14670544
[TBL] [Abstract][Full Text] [Related]
12. Granulomatous hepatitis caused by Bacillus Calmette-Guerin (BCG) infection after BCG bladder instillation.
Leebeek FW; Ouwendijk RJ; Kolk AH; Dees A; Meek JC; Nienhuis JE; Dingemans-Dumas AM
Gut; 1996 Apr; 38(4):616-8. PubMed ID: 8707098
[TBL] [Abstract][Full Text] [Related]
13. Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients.
Pommier JD; Ben Lasfar N; Van Grunderbeeck N; Burdet C; Laouénan C; Rioux C; Pierre-Audigier C; Meybeck A; Choudat L; Benchikh A; Nguyen S; Bouvet E; Yeni P; Yazdanpanah Y; Joly V
Infect Dis (Lond); 2015; 47(10):725-31. PubMed ID: 26077036
[TBL] [Abstract][Full Text] [Related]
14. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
Witjes JA; Fransen MP; van der Meijden AP; Doesburg WH; Debruyne FM
Urol Int; 1993; 51(2):67-72. PubMed ID: 8351757
[TBL] [Abstract][Full Text] [Related]
15. Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.
Witjes JA; vd Meijden AP; Debruyne FM
Urol Int; 1990; 45(3):129-36. PubMed ID: 2190404
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
17. The preparation, handling and use of intravesical bacillus Calmette-Guerin for the management of stage Ta, T1, carcinoma in situ and transitional cell cancer.
Brosman SA; Lamm DL
J Urol; 1990 Aug; 144(2 Pt 1):313-5. PubMed ID: 2374197
[TBL] [Abstract][Full Text] [Related]
18. Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy.
Pisters LL; Tykochinsky G; Wajsman Z
J Urol; 1991 Dec; 146(6):1514-7. PubMed ID: 1942330
[TBL] [Abstract][Full Text] [Related]
19. Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials.
De Jager R; Guinan P; Lamm D; Khanna O; Brosman S; De Kernion J; Williams R; Richardson C; Muenz L; Reitsma D
Urology; 1991 Dec; 38(6):507-13. PubMed ID: 1836081
[TBL] [Abstract][Full Text] [Related]
20. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
Golabek T; Palou J; Rodríguez O; Gaya JM; Breda A; Villavicencio H
World J Urol; 2017 Feb; 35(2):237-243. PubMed ID: 27277599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
